OHR Pharmaceutical Inc (NASDAQ:OHRP) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 3,231,478 shares, a decline of 27.7% from the February 15th total of 4,469,358 shares. Currently, 11.8% of the shares of the stock are short sold. Based on an average trading volume of 739,150 shares, the days-to-cover ratio is currently 4.4 days.
OHRP has been the topic of several research analyst reports. Roth Capital initiated coverage on OHR Pharmaceutical in a research note on Monday, November 27th. They set a “buy” rating and a $7.00 price target on the stock. ValuEngine raised OHR Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
Shares of OHRP stock opened at $0.23 on Wednesday. OHR Pharmaceutical has a 52 week low of $0.21 and a 52 week high of $2.18.
OHR Pharmaceutical (NASDAQ:OHRP) last announced its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.07).
A number of hedge funds have recently bought and sold shares of OHRP. Vanguard Group Inc. lifted its stake in OHR Pharmaceutical by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock valued at $520,000 after buying an additional 5,481 shares in the last quarter. Garrison Bradford & Associates Inc. lifted its stake in OHR Pharmaceutical by 482.4% in the 3rd quarter. Garrison Bradford & Associates Inc. now owns 497,415 shares of the biotechnology company’s stock valued at $358,000 after buying an additional 412,000 shares in the last quarter. Wedbush Securities Inc. lifted its stake in OHR Pharmaceutical by 53.5% in the 4th quarter. Wedbush Securities Inc. now owns 662,909 shares of the biotechnology company’s stock valued at $1,233,000 after buying an additional 230,950 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in OHR Pharmaceutical by 33.2% in the 4th quarter. Renaissance Technologies LLC now owns 1,050,109 shares of the biotechnology company’s stock valued at $1,953,000 after buying an additional 261,700 shares in the last quarter. 10.20% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/21/short-interest-in-ohr-pharmaceutical-inc-ohrp-decreases-by-27-7.html.
OHR Pharmaceutical Company Profile
OHR Pharmaceutical, Inc, a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.